WORK Medical Technology Group LTD Receives 180-Day Extension to Regain Nasdaq Compliance

Hangzhou, China, Oct. 10, 2025 – WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a medical device supplier in China, operating through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its other Chinese subsidiaries, announced today that it has received official notification from The Nasdaq Stock Market LLC (“Nasdaq”). This notification grants the Company an extended 180-calendar-day period to achieve compliance with the minimum bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2) (referred to as the “Rule”).

This notification follows Nasdaq’s initial communication on April 7, 2025, which indicated that WORK Medical’s stock had failed to maintain the minimum bid price for 30 consecutive business days. That initial notice provided WORK Medical a 180-calendar-day period to regain compliance, which subsequently ended on October 6, 2025.

According to the letter issued by Nasdaq on October 7, 2025, WORK Medical qualifies for this additional compliance period, extending until April 6, 2026. This eligibility is based on the Company continuing to meet all other applicable listing requirements for the Nasdaq Capital Market, with the sole exception of the bid price rule. The Company has communicated to Nasdaq its firm intention to resolve the deficiency, including the potential implementation of a reverse stock split if deemed necessary.

To achieve compliance with the Rule, WORK Medical’s stock must maintain a minimum closing bid price of $1.00 per share for a period of at least 10 consecutive business days during this additional compliance period. Nasdaq retains the discretion to mandate that the bid price be upheld for a longer duration, up to 20 days, influenced by factors such as the margin of compliance, trading volume, and the Market Maker montage.

Should WORK Medical fail to regain compliance with the Rule by April 6, 2026, Nasdaq will issue a formal delisting notification. In such an event, the Company retains the right to appeal this determination to a Nasdaq Hearings Panel.

The October 7, 2025, notification from Nasdaq has no immediate impact on the listing or trading status of the Company’s Class A ordinary shares. These shares will continue to trade on the Nasdaq Capital Market under the ticker symbol “WOK.”

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, operates as a supplier of medical devices. The Company is engaged in the development and manufacture of Class I and II medical devices, and also sells Class I and II disposable medical devices via its operating subsidiaries within China. WORK Medical boasts a diverse product portfolio consisting of 21 products, which include custom and multifunctional masks, alongside other medical consumables. All of these products are sold across 34 provincial-level administrative regions in China, with 15 products also being sold in over 30 countries worldwide. The Company has attained several quality-related manufacturing designations and has successfully registered 17 products with the U.S. Food and Drug Administration, thereby enabling their entry into the U.S. market. For additional details, please visit the Company’s website: .

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email:  

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: